Korean Journal of Optometry and Vision Science 2011;10(1):12-22.
Published online June 20, 2011.
망막정맥폐쇄와 연관된 황반부종에서 유리체강 내 트리암시놀론과 베바시주맙 주입술의 효과 비교 및 재발에 대한 분석
장현덕, 이수정, 박정민
Department of Ophthalmology, 1Maryknoll Hospital, 2Haeundae Paik Hospital, Busan, Korea
Comparison of Intravitreal Injection of Triamcinolone and Bevacizumab and Recurrence of Macular Edema with RVO
Hyun Duk Jang, Soo Jung Lee, Jung Min Park
To compare the effect of single intravitreal injection of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, with that of triamcinolone acetonide, a corticosteroid for reduction of macular edema (ME) with retinal vein occlusion and to analyze predisposing factors for recurrence of macular edema. Methods: 116 eyes with macular edema from retinal vein occlusion were enrolled. Single intravitreal injection of 4 mg/0.1 mL triamcinolone (Triamcinolone group) or bevacizumab 1.25 mg/0.05 mL (Bevacizumab group) was done. The clinical course of best-corrected visual acuity (BCVA) worth a logarithm of the minimum angle of resolution chart (LogMAR), intraocular pressure (IOP), averaged central macular thickness (CMT), total macular volume and predisposing factor for recurrence. Results: The bevacizumab injected group with BRVO showed significant improvement of best corrected visual acuity up to six months after the injection. The mean postoperative IOP was significantly increased in triamcinolone injected group. In triamcinolone injected group for ischemic-CRVO, that was significantly increased than Beavacizumab injected group. CMT was significantly reduced in early period of Bevacizumab injected group than triamcinolone injected group. Baseline BCVA was the only predisposing factor of recurrence in Bevacizumab injection for BRVO and duration of retinal vein occlusion to treatment was the one in Bevacizumab injection for CRVO. Conclusions: Bevacizumab injection was better than triamcinolone injection for reducing the central macular thickness in early period of BRVO groups. BRVO patients who benefit from Bevacizumab were significantly good BCVA at baseline than patients with persisting ME. In CRVO patients who benefit from Bevacizumab were significantly early treatment than patients with persisting ME. (Korean J Optom Vis Sci 2011; 10(1):12-22)
Key Words: Bevacizumab, Macular edema, Retinal vein occlusion, Triamcinolone

Editorial Office
Korea University Anam Hospital, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea
Tel: +82-2-2271-6603    Fax: +82-2-2277-5194    E-mail: journal@annocl.org                

Copyright © 2022 by The Korean Optometry Society and The Korean Contact Lens Study Society.

Developed in M2PI

Close layer
prev next